Blog

Oct 2, 2026

Retatrutide reported larger average weight loss than tirzepatide in phase 3 trials, but it is not an available treatment. In TRIUMPH-1, retatrutide 12mg was reported to produce 28.3% mean weight reduction at 80 weeks; tirzepatide produced 20.2% at 72 weeks in the peer-reviewed head-to-head SURMOUNT-5 trial. Tirzepatide is FDA-approved and prescribable today. Retatrutide is investigational: […]

Sep 23, 2026

GLP-1 medications are a class of injectable and oral drugs that mimic glucagon-like peptide-1, an incretin hormone the gut releases after eating, to lower blood glucose and reduce appetite. The class has been in clinical use since 2005 and now spans seven molecules across roughly a dozen brand names, approved for type 2 diabetes, chronic […]

Sep 15, 2026

Ozempic (semaglutide) is not recommended during pregnancy, and the FDA-approved prescribing information advises discontinuing it at least 2 months before a planned pregnancy. The washout period reflects semaglutide’s elimination half-life of approximately one week, which means roughly five weeks are required for 97% clearance, plus a deliberate safety margin. Animal reproduction studies showed embryo-fetal harm […]

Sep 8, 2026

Ozempic (semaglutide) has a US list price of approximately $968 to $1,029 per month as of April 2026, but most uninsured patients do not pay this amount. Through NovoCare Pharmacy and GoodRx’s Novo-backed program, Ozempic is available to eligible cash-pay patients at $349 per month for 0.25mg, 0.5mg, and 1mg doses, or $499 per month […]

Aug 26, 2026

Ozempic (semaglutide 0.5mg, 1mg, 2mg) is FDA-approved for type 2 diabetes and produces gastrointestinal side effects in the majority of patients — primarily nausea, diarrhea, vomiting, and constipation — most prominently during dose escalation. These effects are dose-dependent and class-wide across all GLP-1 receptor agonists. In the SUSTAIN-1 trial, nausea occurred in approximately 15 to […]

Aug 18, 2026

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both weekly injectable GLP-1 receptor agonists used for weight management and metabolic disease, but they work through different mechanisms and produce substantially different outcomes. Tirzepatide adds GIP receptor agonism to GLP-1 receptor activation, producing greater average weight loss (approximately 20% vs. 15% in head-to-head SURMOUNT-5 data), stronger glucose lowering, […]

Aug 10, 2026

Wegovy and Ozempic contain the same active ingredient — semaglutide — but they are different products with different FDA approvals, different doses, and critically different insurance coverage implications. Wegovy (semaglutide 2.4mg) is FDA-approved for chronic weight management. Ozempic (semaglutide 0.5mg, 1mg, 2mg) is FDA-approved for type 2 diabetes. Using one when you need the other […]

Aug 1, 2026

Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes — not for weight loss. However, off-label prescribing for weight management is common in clinical practice, and the molecule’s weight loss data from the SURMOUNT trials (up to 20.2% body weight reduction) is among the strongest in obesity pharmacology. Zepbound is the same tirzepatide molecule with an […]

Jul 26, 2026

Compounded tirzepatide was legally available in the United States from 2022 to early 2025 during the FDA drug shortage period, but enforcement deadlines have since passed and routine compounding is no longer legally supported. The FDA resolved the tirzepatide shortage in December 2024 and set enforcement deadlines of February 19, 2025 for 503A pharmacies and […]

Jul 17, 2026

Compounded semaglutide is not FDA-approved and has not been evaluated for safety, potency, or sterility by the FDA. It was legally available during the period when semaglutide was on the FDA drug shortage list (2022 to 2025), allowing licensed compounding pharmacies to produce it under specific regulatory conditions. On February 21, 2025, the FDA issued […]

Jul 10, 2026

Wegovy (semaglutide 2.4mg) produces gastrointestinal side effects in the majority of patients, most commonly nausea, vomiting, diarrhea, and constipation. These occur predominantly during dose escalation and typically diminish at stable maintenance doses. In STEP-1, 44% of participants on Wegovy reported nausea vs. 16% on placebo, and 4.5% discontinued due to GI adverse events. Beyond GI […]

Jul 2, 2026

Retatrutide (LY3437943) is an investigational once-weekly injection from Eli Lilly that activates three metabolic receptors simultaneously — GIP, GLP-1, and glucagon — producing the highest average weight loss ever recorded in a Phase 3 clinical trial. In TRIUMPH-1 (May 2026), adults with obesity on the 12mg dose lost a mean of 28.3% of body weight […]